TIGIT / VSTM3 Protein Price Inquiry ( Available Sizes )
TIGIT / VSTM3 Protein Product Information
| Synonym : |
ENSMUSG00000071552, Vstm3 |
| Protein Construction: |
A DNA sequence encoding the extracellular domain of mouse TIGIT (NP_001139797.1) (Met 1-Gly 141) was expressed, with a C-terminal polyhistidine tag. |
| Source: |
Mouse |
| Expression Host: |
Human Cells |
TIGIT / VSTM3 Protein QC Testing
| Purity: |
> 90% as determined by SDS-PAGE. |
SDS-PAGE:

TIGIT / VSTM3 protein
|
| Endotoxin: |
< 1.0 EU per μg of the protein as determined by the LAL method |
| Stability: |
Samples are stable for up to twelve months from date of receipt at -70℃ |
| Predicted N terminal: |
Gly 26 |
| Molecular Mass: |
The secreted recombinant mouse TIGIT comprises 127 amino acids and has a calculated molecular mass of 14.2 kDa. As a result of glycosylation, the apparent molecular mass of rmSIRPA is approximately 20-25 kDa in SDS-PAGE under reducing conditions. |
| Formulation: |
Lyophilized from sterile PBS , pH 7.4
- Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
- Please contact us for any concerns or special requirements.
|
TIGIT / VSTM3 Protein Usage Guide
| Storage: |
Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Reconstitution: |
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information. |
TIGIT / VSTM3 Protein Related Products & Topics
Related Areas:
Proteins:
Antibodies:
TIGIT / VSTM3 Protein Description
TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-10 and diminished the production of IL-12p40. In addition, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.
References
- Yu X. et al., 2009, Nat Immunol. 10 (1): 48-57.
- Stanietsky N. et al., 2009, Proc Natl Acad Sci.106 (42):17858-63.